about
Dual roles of p300 in chromatin assembly and transcriptional activation in cooperation with nucleosome assembly protein 1 in vitro.Vav2 activates c-fos serum response element and CD69 expression but negatively regulates nuclear factor of activated T cells and interleukin-2 gene activation in T lymphocyteCherubism allele heterozygosity amplifies microbe-induced inflammatory responses in murine macrophages.The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasionMetformin inhibits melanoma development through autophagy and apoptosis mechanisms.Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway.The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity.Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation.Comparative oncogenomics identifies tyrosine kinase FES as a tumor suppressor in melanoma.SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness.Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis.Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and proliferation and invasion assays.LIF mediates proinvasive activation of stromal fibroblasts in cancer.Technical advance: actin CytoFRET, a novel FRET flow cytometry method for detection of actin dynamics in resting and activated T cell.Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner.SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival.Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.In vitro and in vivo anti-melanoma effects of ciglitazone.Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.SPARC represses E-cadherin and induces mesenchymal transition during melanoma development.HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1.Pathological prion protein exposure switches on neuronal mitogen-activated protein kinase pathway resulting in microglia recruitment.Regulation of secreted protein acidic and rich in cysteine during adipose conversion and adipose tissue hyperplasia.Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-dependent pathway.Prostaglandin E2 induces interaction between hSlo potassium channel and Syk tyrosine kinase in osteosarcoma cells.The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.A non-coding function of TYRP1 mRNA promotes melanoma growth.The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression.Identification by mutation of the tyrosine residues in the insulin receptor substrate-1 affecting association with the tyrosine phosphatase 2C and phosphatidylinositol 3-kinaseGene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survivalHypoxia and MITF control metastatic behaviour in mouse and human melanoma cellsTumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling PathwayA feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanomaResistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
P50
Q24293575-4603DE45-C30A-434E-AB47-36EDE0B86788Q28206048-03A4369B-8005-4E95-9D27-D6EAFCB8AAA6Q30009218-433A2625-9D0D-492A-9F2A-38778A936AAEQ34387472-14ABE8B3-C559-41BF-AE37-E4937453FC63Q35269865-B1594585-96F8-4473-8841-429791EC5738Q36926143-44E4570E-7EC5-4FB6-B5A7-39E1C237450FQ38302172-2E55E524-D363-49E9-AC3B-DF826E96F297Q38358677-82E884E5-7CD3-49FF-80F3-0873667795B0Q38809327-AC36C8A0-6685-4945-9936-2D7EC5D2D812Q38813744-AA7B8D15-AA98-4E94-8C30-40C55A720C76Q38880787-FFAE6109-C7D0-4675-B7C8-B93C5A128E3EQ38985828-B3BB9625-4396-4623-88C1-E8C51606629FQ38992217-00BF8F2B-E647-45AC-8612-F83F3DEB18BAQ39136007-0325D606-6288-413D-9F1F-F938B288BD0FQ39143352-3ED29F33-03B5-45B4-8120-B6A0F130A41EQ39521848-E7A728C5-AF3A-4412-94DE-53BCE775CE66Q39628692-1B676807-0F00-481D-9406-E31299FDE34BQ39889800-C5C9D042-DF5A-4AFC-9B9F-6E9B740410F9Q40039631-3549A86E-F57F-4884-9B45-DDD132D4996AQ40248571-2124BB5B-7C4D-4A1C-A29D-8387BC0401FCQ40479151-1A64AF20-26CF-4E68-80AF-55609115C9F6Q40495541-0BFFE596-3A4F-4656-8FC1-1B25BB7ADE94Q42833163-F87B7A08-A094-497A-9352-82BA3F143EC6Q43891668-5E8F7978-8FBD-45FE-B05D-BC3ACDCAC03CQ43991825-F9C9C739-5783-44B7-AB64-8C2ECABB74A1Q45937702-8D7E91C7-E267-48E8-9D2F-BD6B568CF987Q47678258-1557F76F-2C4E-41EB-9BB3-935F3D44092DQ54641862-784B6FC1-E17B-44D3-B81F-B5BCA752305EQ57461675-CE57AC8F-081D-490C-AAA5-8B0F5C423B21Q58034882-7A081C0F-0ACD-4FDE-9CC4-32BC2A666831Q61349793-69E10B59-6A2E-4736-B035-0909AAE1A8AAQ61350147-DD4DE284-614D-4C7F-9098-4068C85A31C0Q90369547-94E129C2-5294-4E7F-88E3-A5C077F25877Q92889972-B72854E9-EA5F-42A7-A970-2DC30DF18CCF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sophie Tartare-Deckert
@ast
Sophie Tartare-Deckert
@en
Sophie Tartare-Deckert
@es
Sophie Tartare-Deckert
@nl
type
label
Sophie Tartare-Deckert
@ast
Sophie Tartare-Deckert
@en
Sophie Tartare-Deckert
@es
Sophie Tartare-Deckert
@nl
prefLabel
Sophie Tartare-Deckert
@ast
Sophie Tartare-Deckert
@en
Sophie Tartare-Deckert
@es
Sophie Tartare-Deckert
@nl
P106
P21
P31
P496
0000-0001-8680-5720